Journal article
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation
Abstract
BACKGROUND: We aimed to estimate absolute benefit and harm from treatment with dabigatran in individual patients with atrial fibrillation, and to select the optimal dose for each individual.
METHODS: We derived and validated a prediction model for ischemic stroke/systemic embolism and major bleeding in patients with atrial fibrillation from the 3 treatment arms of the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy With …
Authors
Stam-Slob MC; Connolly SJ; van der Graaf Y; van der Leeuw J; Dorresteijn JAN; Eikelboom JW; Peters RJG; Alings M; Visseren FLJ
Journal
Circulation, Vol. 139, No. 25, pp. 2846–2856
Publisher
Wolters Kluwer
Publication Date
June 18, 2019
DOI
10.1161/circulationaha.118.035266
ISSN
0009-7322
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAnticoagulantsAntithrombinsAtrial FibrillationClinical Decision-MakingDabigatranDecision Making, SharedDecision Support TechniquesFemaleHemorrhageHumansMalePatient SelectionPredictive Value of TestsRandomized Controlled Trials as TopicReproducibility of ResultsRisk AssessmentRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarin